论文部分内容阅读
目的研究磺脲类受体1(SUR1)基因16-3C/T多态性对格列齐特降糖疗效的影响。方法153名2型糖尿病患者服用格列齐特8周,用水解探针技术检测病人SUR116-3C/T多态性,比较不同基因型患者治疗前后血糖、HbA1c、HOMA-β、HOMA-IR的变化。结果基线水平时3种基因型患者的临床表型相似,治疗结束后T/T纯合子患者HbA1c下降和HOMA-β上升程度明显高于其他基因型患者(P均<0.050)。结论16-3C/T多态性对格列齐特的降糖疗效有修饰作用,T/T型患者服用格列齐特后胰岛β细胞功能明显提高,取得较好的HbA1c控制。
Objective To investigate the effect of 16-3C / T polymorphism of sulfonylurea receptor 1 (SUR1) gene on the therapeutic effect of gliclazide. Methods 153 patients with type 2 diabetes were treated with gliclazide for 8 weeks. The SUR116-3C / T polymorphism was detected by hydrolysis probe technique. The levels of blood glucose, HbA1c, HOMA-β and HOMA-IR in patients with different genotypes before and after treatment were compared Variety. Results The clinical phenotypes of three genotypes were similar at baseline. After treatment, HbA1c and HOMA-β levels in T / T homozygous patients were significantly higher than those in other genotypes (all P <0.050). Conclusion 16-3C / T polymorphism can modify the hypoglycemic effect of gliclazide. The function of β-cell after Gliclazide treatment in T / T patients is obviously improved, and HbA1c is better controlled.